Kano Therapeutics

The magic of Kendall Sq! Seth Ettenberg is joining Kano Therapeutics Board of directors. “Kano has developed a transformative technology and is ready to commercialize its circular ssDNA gene templates. I'm thrilled to support the team to scale their partnership portfolio and enable genomic medicines.” Seth Ettenberg, PhD, is the President and CEO at BlueRock Therapeutics. Seth joined BlueRock as CSO in 2020 and led the rapid expansion and advancement of BlueRock’s pipeline. Prior to joining BlueRock, Seth was a founding member of Unum Therapeutics where he served as CSO. At Unum Seth built and led the strategy team that supported strategic partnerships, four first in class clinical trials, several rounds of fundraising, and a successful NASDAQ IPO listing. Previously Seth led the Cambridge site of Novartis’ Oncology Biotherapeutics group where he was responsible for developing and leading the strategy and implementation for oncology drug development projects at the Novartis Institutes for Biomedical Research (NIBR). In addition, Seth was responsible for building and leading the Novartis Cell and Gene Therapy research team in collaboration with the University of Pennsylvania to develop chimeric antigen receptor T-cell therapeutics. Seth received his formal scientific training at the Genetics Branch of the National Cancer Institute. As a LabCentral alumni, Seth knows what it means to start a company from scratch. He is joining Kano’s board as the first Independent board director and will work alongside Vinny Beranek and Ann DeWitt from Engine Ventures and Lise Rechsteiner, PhD Rechsteiner from Vsquared Ventures.

It is bittersweet to wrap up my time at Kano Therapeutics! I have spent the past six months working on the Process Development team at Kano, where I contributed to cutting-edge gene therapy development through circular single-stranded DNA production with bacterial fermentation techniques, downstream processing, and analytical development. In addition to performing quality control assays on DNA produced by the team, I honed in on developing new analytical methods and systems, including onboarding new assays and developing fluidics automation systems. I also had the opportunity to analyze and interpret DNA sequencing results, design DNA primers and plasmid maps, and work on cloning projects. A big thank-you to Scott Hamilton for being a fantastic supervisor and mentor, Christian Burns, Nicholas Gentile and Beaven Ankner-Edelstein for teaching me so much along the way, Greg Foley, Maggie Bara, Alline R Pacheco, PhD, and Kimberly Wong for exposing me to the work of the other teams and answering all my questions, and Floris Engelhardt and John Vroom for their inspiring leadership. While I am looking forward to what is coming next, I will miss working alongside such wonderful and driven individuals.

CEO Floris Engelhardt is Boston Business Journal 2024 Woman Who Lead in Life Sciences Honoree.

Exactly two years ago on September 6th I joined Kano! We like to joke about me being the first employee but it has been so special to see everything and everyone, especially myself, grow! So of course I wanted to be silly and wear the same outfit that I did on my first day and get another group photo. Thank you Floris Engelhardt and John Vroom for these very special two years that I get to look back on as I continue working alongside every amazing person here, and also for suggesting to take a picture on the skybridge (I am afraid of heights).

"Secured an oversubscribed $5 million seed round. The Engine Ventures and Vsquared Ventures co-led the round, with Taihill Venture and Metaplanet also participating. The round brings Kano’s total funding to date to $7.1 million." https://lnkd.in/efiqwCzj We are absolutely thrilled to be working with Engine Ventures, Amino Collective, Vsquared Ventures, Metaplanet, and Taihill Venture. Also included in our gratitude must be Jacob Becraft, Jacob Corn, Brian Shy, and Stephen Sofen. Thanks to Walker Comms for working with us on this announcement.

In 2021, during the Nucleate Activator program, I first discovered Endpoints News — proof of how new I was to biopharma! Now, after being a subscriber for three years, I have the opportunity to share this article with you, written by the phenomenal Ryan Cross. https://lnkd.in/ePnx9TfD I need thank my co-founders John Vroom, Mark Bathe and some special organizations that have guided me from coming to the US in 2020 to leading an organization with the most fantastic scientists and developing therapeutic opportunities for gene insertions at Kano Therapeutics. Massachusetts Institute of Technology, UMass Boston, Activate, The Termeer Foundation, The Engine, Engine Ventures, Vsquared Ventures, Amino Collective, Metaplanet, Taihill Venture

Explore our newest roles and join a team that's at the forefront of scientific innovation: 🌟 Senior Scientist, Downstream Process Development & Analytics 🔗 Apply Now: https://lnkd.in/eBusJGPB 🌟 Sr. Research Associate/Scientist, Mammalian Cell Genome Editing 🔗 Apply Now: https://lnkd.in/ecJrDsZE Discover more about our career opportunities and how you can make an impact: 🔗 https://lnkd.in/e7fVWf2e

We are thrilled to announce that we’ve been selected as a spoke of the Advanced Research Projects Agency for Health (ARPA-H) Investor Catalyst Hub network! We are excited to contribute to the community.

We're hiring! Kano is seeking a discovery research scientist to help bring our early pipeline programs closer to patients. If you're interested in joining our team apply here: https://lnkd.in/dSK-YXiQ